文献速递类风湿关节炎

托法替布与生物制剂治疗类风湿关节炎的恶性肿瘤风险:系统评价、荟萃分析与网状荟萃分析

Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2017-02-16

该系统评价纳入2000年至2015年2月的113篇文章及1份更新报告,比较随机对照试验(RCT)和长期扩展研究(LTE)中生物DMARDs与托法替布治疗类风湿关节炎(RA)的恶性肿瘤风险。RCT荟萃分析显示各药物总体恶性肿瘤风险比值比均无显著增加,网状荟萃分析结果类似;LTE中实体瘤、血液系统恶性肿瘤和非黑色素瘤皮肤癌发生率出现边缘数值差异,需持续药物警戒。

要点

  • RCT中生物DMARDs或托法替布治疗RA未增加恶性肿瘤风险。
  • LTE中特定恶性肿瘤发生率出现边缘数值差异,需真实世界持续监测。
  • 网状荟萃分析各药物总体恶性肿瘤风险比值比均无显著差异。

核心结论

  • 在RCT中,使用生物DMARDs或托法替布治疗RA不增加恶性肿瘤风险。
  • LTE中观察到的特定恶性肿瘤发生率差异的普遍性需对真实世界患者进行持续药物警戒。

研究设计与样本

  • 系统评价、荟萃分析与网状荟萃分析,检索Medline、Embase、Cochrane Library和Web of Science 2000年至2015年2月的文献。
  • 纳入标准为聚焦RA的RCT或LTE、使用生物DMARDs或托法替布、报告恶性肿瘤数据、随访至少12周。
  • 共对113篇文章和1份更新报告进行荟萃分析。

主要发现

  • RCT中总体恶性肿瘤比值比(95%CI)为:所有TNF拮抗剂1.01(0.72,1.42),阿巴西普1.12(0.33,3.81),利妥昔单抗0.54(0.20,1.50),托珠单抗0.70(0.20,2.41),托法替布2.39(0.50,11.5)。
  • 网状荟萃分析总体恶性肿瘤比值比(95%预测区间)为:英夫利西单抗1.68(0.48-5.92),依那西普0.79(0.44-1.40),阿达木单抗0.93(0.43-2.03), certolizumab 0.87(0.28-2.75),戈利木单抗0.87(0.39-1.95),阿巴西普1.04(0.32-3.32),利妥昔单抗0.58(0.21-1.56),托珠单抗0.60(0.16-2.28),托法替布1.15(0.24-5.47)。
  • LTE中实体瘤、血液系统恶性肿瘤和非黑色素瘤皮肤癌的发生率出现边缘数值差异。

临床怎么用

  • RCT证据表明生物DMARDs或托法替布治疗RA不增加总体恶性肿瘤风险,可据此进行临床决策。
  • 对LTE中特定恶性肿瘤发生率的边缘差异,应在真实世界患者中持续进行药物警戒。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To summarize and compare the risks of malignancies accompanying biologic DMARDs (b-DMARDs) and tofacitinib in rheumatoid arthritis (RA) in randomized clinical trials (RCTs) and long-term extension studies (LTEs). METHODS: Articles in Medline, Embase, Cochrane Library, and the Web of Science dated from 2000 to February 2015. Selection criteria were as follows: (1) focus on RCTs or LTEs in RA; (2) treatment with b-DMARDs or tofacitinib; (3) data on malignancies; and (4) a minimum follow-up of 12 weeks. Data included publication details, study design, risk of bias, number and types of malignancies, and patient characteristics and treatments. DATA SYNTHESIS: Of 113 articles and one updated report that were meta-analyzed, overall malignancies in RCTs showed odds ratio (95% confidence intervals) of 1.01 (0.72, 1.42) for all TNF antagonists, 1.12 (0.33, 3.81) for abatacept, 0.54 (0.20, 1.50) for rituximab, 0.70 (0.20, 2.41) for tocilizumab, and 2.39 (0.50, 11.5) for tofacitinib. Network meta-analysis of overall malignancies showed odds ratio (95% predictive intervals) of 1.68 (0.48-5.92) for infliximab, 0.79 (0.44-1.40) for etanercept, 0.93 (0.43-2.03) for adalimumab, 0.87 (0.28-2.75) for certolizumab, 0.87 (0.39-1.95) for golimumab, 1.04 (0.32-3.32) for abatacept, 0.58 (0.21-1.56) for rituximab, 0.60 (0.16-2.28) for tocilizumab, and 1.15 (0.24-5.47) for tofacitinib. Marginal numerical differences in the incidence rate of solid and hematological malignancies and non-melanoma skin cancers appeared in LTEs. CONCLUSIONS: In RCTs, treatment of RA with b-DMARDs or tofacitinib does not increase the risk for malignancies. Generalizability of the differences in the rate of specific malignancies encountered in LTEs requires continuous pharmacovigilance of real-world patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Maneiro JR, Souto A, Gomez-Reino JJ, et al. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 2017. PMID: 28284845. doi:10.1016/j.semarthrit.2017.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。